Psychiatry AdvisorTardive Dyskinesia Impact Scale Is a High Precision Tool for Assessing Treatment Effects

✅ Clinical Decision Support / Validated Tool
A Journal of Clinical Psychiatry review evaluated the Tardive Dyskinesia Impact Scale (TDIS) using pooled data from the KINECT 3 and KINECT 4 valbenazine trials in 388 adults with mood disorders or schizophrenia. The analysis assessed discrimination, precision, and a minimal clinically important difference threshold against established clinician-reported outcomes.

Clinical Considerations

• Seven of 8 physical function items and all 3 socioemotional items showed high discrimination in differentiating impairment levels across patients.
• A 4-point change in total TDIS score was estimated as the minimal clinically important difference, with most KINECT trial completers meeting or exceeding this threshold.
• Baseline TDIS showed low-to-moderate correlation with AIMS (r=0.31), suggesting the patient-reported and clinician-rated tools capture distinct dimensions of TD burden.
• The review was authored by Neurocrine Biosciences (valbenazine manufacturer) and Zucker Hillside Hospital, and validation data come exclusively from valbenazine trials.

Practice Applications

• Consider TDIS alongside clinician-rated AIMS to capture the patient-experienced burden of TD.
• Recognize a 1-point change in any individual TDIS item as clinically meaningful in routine assessment.
• Integrate patient-reported outcomes when documenting TD severity, treatment response, and shared decision-making.
• Interpret validation findings within the context of industry-sponsored trial data and a single VMAT2 inhibitor.